For a lab working on neurodegeneration, that focus is exactly what you want to see first
However, some conflicting results question the efficacy of BDNF as a mediator of tau phosphorylation
It reflects what you are not paying for at the cheap end: no provider involvement, no individualized dosing, no injection training, no sterile reconstitution guidance, and no recourse if you have a reaction
The timeframe for observing results also plays a role short-term effects might call for a single, higher dose, while long-term studies may benefit from smaller, repeated doses
Due to its dual-peptide profile, it is frequently examined in structured investigations focusing on signalling pathway interaction, recovery-response dynamics, and peptide stability within controlled research environments